Tiny technology,
for a sustainable future
Pharma
Inhalers that are based on Medspray’s nozzle technology, achieve a very high lung dose. Its use results in a lung dose up to 3 to 4 times larger than conventional pMDIs or dry powder inhalers. By tailoring the droplet size and controlling the inhalation air flow during inhalation, we can target the drug to the upper lung (e.g. asthma bronchodilators), the central lung (e.g. antibiotic treatment), or for fast systemic uptake into the blood stream by targeting the deep lung (e.g. medication to control pulmonary hypertension).
Less degradation of biological formulations
Classical nebulization methods (ultrasonic, vibrating mesh) may easily damage biological drug formulations, (e.g. RNA, antibodies, complex proteins, vaccines, phages, etc), because a lot of energy is dissipated in the formulation during nebulization. The energy to drive Medspray’s nebulization technology is typically 50 times less in comparison with classical nebulizers, resulting in a substantial lower loss (typically more than 10 times less) of the biological active pharmaceutical ingredient (e.g. lipid based nanoparticle formulations).
Extend product life cycle
New drug delivery devices are the future when it comes to product life cycle extension of inhalers. Medspray inhalers can offer you an extended product protection of existing API’s by more specific targeting with a high efficacy resulting in less (unwanted) systemic side effects.
Get in touch for your product!
Ask our team about your options.
We reply within 2 business days.
Send a quick message
Meet the Ecomyst90!
The Ecomyst90 combines the pump system of Aeropump and the innovative Medspray spray nozzle technology. A unique preservative and propellant-free liquid inhaler that delivers an ultra- fine and dosed spray. The Ecomyst90 product benefits speak for themselves: no propellant, no preservatives, precise dosing!
For more information and technical details on the Ecomyst90, click here.